Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00930280 · ClinicalTrials.gov registry record
Genetic and Environmental Risk Factors for Hemorrhagic Stroke-GERFHS III
A clinical trial of Stroke, sponsored by University of Cincinnati.
- Active
- Registry status
- 1,260
- Enrollment target
- 1
- Study location
NCT00930280: Active study of Stroke, sponsored by University of Cincinnati.
NCT00930280 is a study of Stroke that is active but no longer recruiting, run by University of Cincinnati. The registered enrollment target is 1,260 participants, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00930280, a study of Stroke, is active but no longer recruiting, sponsored by University of Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- 1,260 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find risk factors for hemorrhagic stroke, specifically intracerebral hemorrhage (ICH). ICH, a type of bleeding into brain tissue, is a type of stroke that can result in death or disability in a large number of people. Our study hopes to identify a specific genetic risk factor that will help identify at risk individuals and target treatment strategies.
Conditions Studied
Study Locations (1)
Ohio
- University of Cincinnati Department of Neurology - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,260 participants |
| Start Date | 2008-07 |
| Est. Completion | 2025-06 |
What the registry record for NCT00930280 still lists
NCT00930280 is an observational study that tracks outcomes without assigning an intervention. Its 1,260 participants enrollment target places it among the larger protocols in the corpus, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 0 interventions.
NCT00930280 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00930280 about?
NCT00930280 is a clinical study titled "Genetic and Environmental Risk Factors for Hemorrhagic Stroke-GERFHS III". The purpose of this study is to find risk factors for hemorrhagic stroke, specifically intracerebral hemorrhage (ICH). ICH, a type of bleeding into brain tissue, is a type of stroke that can result in death or disability in a large number of people. Our study hopes to identify a specific genetic ris...
What is the current status of trial NCT00930280?
This trial is currently active not recruiting. The enrollment target is 1,260 participants. The study started on 2008-07. Estimated completion is 2025-06.
What conditions does trial NCT00930280 study?
This clinical trial studies the following conditions: Stroke.
Who is sponsoring clinical trial NCT00930280?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00930280 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00930280's enrollment target sits among peer trials
1,260 32nd of 454 higher than 423 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
RECRUITING
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
RECRUITING
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia